| P50 | author | Jules Angst | Q125668 |
| | Hans-Jürgen Möller | Q1577771 |
| | Peter C. Whybrow | Q2074257 |
| | Michael Bauer | Q56953337 |
| | Emanuel Severus | Q100296720 |
| P2093 | author name string | Stephan Köhler | |
| | Wfsbp Task Force on Treatment Guidelines for Unipolar Depressive Disorders | |
| P2860 | cites work | Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis | Q22242068 |
| | A different depression: clinical distinctions between bipolar and unipolar depression | Q45263073 |
| | Evidence-based definitions of bipolar-I and bipolar-II disorders among 5,635 patients with major depressive episodes in the Bridge Study: validity and comorbidity | Q45748197 |
| | The lithiumeter: a measured approach | Q45862905 |
| | A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. | Q46326672 |
| | Adjunctive lithium treatment in the prevention of suicidal behaviour in depressive disorders: a randomised, placebo-controlled, 1-year trial | Q46353446 |
| | Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial | Q46435141 |
| | Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression | Q46732812 |
| | The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness | Q47284701 |
| | Effects of maintenance electroconvulsive therapy on cognitive functions | Q47627147 |
| | Pattern of cognitive dysfunction in depressive patients during maintenance electroconvulsive therapy | Q48371961 |
| | Is it possible to evaluate true prophylactic efficacy of antidepressants in severely ill patients with recurrent depression? Lessons from a placebo-controlled trial. The fifth trial of the Danish University Antidepressant Group (DUAG-5). | Q48519954 |
| | Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study | Q49066243 |
| | Maintenance strategies for unipolar depression: an observational study of levels of treatment and recurrence | Q50167324 |
| | Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. | Q50733742 |
| | Head to head comparisons as an alternative to placebo-controlled trials. | Q50775247 |
| | A controlled family history study of childhood-onset depressive disorder. | Q50944717 |
| | Continuation/maintenance treatment with nortriptyline versus combined nortriptyline and ECT in late-life psychotic depression: a two-year randomized study. | Q51890154 |
| | Impact of maintenance ECT on concentration and memory. | Q51964026 |
| | Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. | Q51988085 |
| | The course of depression in adult outpatients. Results from the Medical Outcomes Study | Q52041345 |
| | Methodologic issues in maintenance therapy clinical trials. | Q52051116 |
| | Mortality during initial and during later lithium treatment. A collaborative study by the International Group for the Study of Lithium-treated Patients. | Q53015585 |
| | Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. | Q53884881 |
| | Has the effectiveness of lithium changed? Impact of the variety of lithium's effects. | Q54132465 |
| | Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. | Q55051636 |
| | Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction. | Q55052151 |
| | Lithium Treatment Reduces Suicide Risk in Recurrent Major Depressive Disorder | Q55887063 |
| | Family psychoeducation for major depression: randomised controlled trial | Q56777212 |
| | The P revention of R ecurrent E pisodes of Depression with Ven lafaxine for T wo Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases | Q57616556 |
| | The clinical course of unipolar major depressive disorders | Q41641015 |
| | Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression | Q41758421 |
| | Lithium treatment and prophylaxis in unipolar depression: a meta-analysis | Q42113366 |
| | Effects of antidepressant pharmacotherapy after repetitive transcranial magnetic stimulation in major depression: an open follow-up study | Q42167257 |
| | Maintenance study for adolescent depression | Q42596017 |
| | Escitalopram prevents relapse in older patients with major depressive disorder | Q42624370 |
| | Fluoxetine in the prevention of depressive recurrences: a double-blind study. | Q42655664 |
| | Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial | Q42928152 |
| | Duloxetine 60 mg/day for the prevention of depressive recurrences: post hoc analyses from a recurrence prevention study | Q43117497 |
| | Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. | Q43292973 |
| | Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. V. Complementary and alternative medicine treatments. | Q43295442 |
| | Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy | Q43562596 |
| | Subjective response to and tolerability of long-term supraphysiological doses of levothyroxine in refractory mood disorders | Q43568188 |
| | Cognitive-behavioral therapy as continuation treatment to sustain response after electroconvulsive therapy in depression: a randomized controlled trial | Q43637112 |
| | Diagnostic conversion from depression to bipolar disorders: results of a long-term prospective study of hospital admissions | Q43922336 |
| | Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy | Q44045879 |
| | How long should the lithium augmentation strategy be maintained? A 1-year follow-up of a placebo-controlled study in unipolar refractory major depression. | Q44097699 |
| | Older community residents with depression: long-term treatment with sertraline. Randomised, double-blind, placebo-controlled study | Q44460107 |
| | Maintenance cognitive-behavioral therapy and manualized psychoeducation in the treatment of recurrent depression: a multicenter prospective randomized controlled trial | Q44541432 |
| | A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder | Q44879548 |
| | Long-term lithium and mortality | Q45008001 |
| | Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. I. Classification, burden and principles of management | Q45072698 |
| | Cognitive behavioural therapy for major psychiatric disorder: does it really work? A meta-analytical review of well-controlled trials | Q22251387 |
| | Antidepressant-associated mood-switching and transition from unipolar major depression to bipolar disorder: A review | Q22252404 |
| | Change in mental health after smoking cessation: systematic review and meta-analysis | Q22306548 |
| | Antidepressant discontinuation syndromes | Q28188383 |
| | Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression: acute and chronic effects | Q28278628 |
| | Interpersonal psychotherapy for depression: a meta-analysis | Q28306300 |
| | The effect of mindfulness-based cognitive therapy for prevention of relapse in recurrent major depressive disorder: A systematic review and meta-analysis | Q29026312 |
| | World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthre | Q31121202 |
| | World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder | Q31121208 |
| | Systematic review and guide to selection of selective serotonin reuptake inhibitors | Q33611926 |
| | Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. | Q33667966 |
| | Should depression be managed as a chronic disease? | Q33804146 |
| | Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology | Q33886704 |
| | The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study | Q34012028 |
| | Relapse prevention in major depressive disorder after successful ECT: a literature review and a naturalistic case series | Q34120970 |
| | Chronic depression in the elderly: approaches for prevention. | Q34324751 |
| | Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials | Q34333771 |
| | Rapid effects of deep brain stimulation for treatment-resistant major depression | Q34337593 |
| | Cognitive status of psychiatric patients under maintenance electroconvulsive therapy: a one-year longitudinal study | Q34379243 |
| | Clinically significant pharmacokinetic drug interactions with carbamazepine. An update | Q34403438 |
| | Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis | Q34424402 |
| | Do current screening recommendations allow for early detection of lithium-induced hyperparathyroidism in patients with bipolar disorder? | Q34503303 |
| | Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. | Q34507312 |
| | Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial | Q34514200 |
| | Australian and New Zealand clinical practice guidelines for the treatment of depression | Q34548787 |
| | Managing the risk of lithium-induced nephropathy in the long-term treatment of patients with recurrent affective disorders | Q34582543 |
| | Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE) | Q34587351 |
| | Safety and efficacy of Vagus Nerve Stimulation in treatment-resistant depression. A systematic review | Q34589824 |
| | Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines | Q34590507 |
| | The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania | Q34606256 |
| | The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression | Q34616633 |
| | Lithium toxicity profile: a systematic review and meta-analysis | Q34635275 |
| | A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder | Q34637400 |
| | ??? | Q28281197 |
| | The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder | Q34649187 |
| | Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial | Q34748493 |
| | World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision | Q34865036 |
| | Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies | Q34995758 |
| | Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials | Q34997918 |
| | Renal failure occurs in chronic lithium treatment but is uncommon | Q35014656 |
| | Continuation and maintenance electroconvulsive therapy for mood disorders: review of the literature | Q35226595 |
| | A consensus statement for safety monitoring guidelines of treatments for major depressive disorder | Q35311467 |
| | Delivering interventions for depression by using the internet: randomised controlled trial | Q35629358 |
| | Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression | Q35848774 |
| | Lithium: a review of its metabolic adverse effects | Q36262539 |
| | Number Needed to Treat to Harm for Discontinuation Due to Adverse Events in the Treatment of Bipolar Depression, Major Depressive Disorder, and Generalized Anxiety Disorder With Atypical Antipsychotics | Q36275903 |
| | Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial | Q36514240 |
| | Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial | Q36810994 |
| | Reducing relapse and recurrence in unipolar depression: a comparative meta-analysis of cognitive-behavioral therapy's effects | Q37070494 |
| | What is the optimal serum lithium level in the long-term treatment of bipolar disorder--a review? | Q37083723 |
| | Individualized continuation electroconvulsive therapy and medication as a bridge to relapse prevention after an index course of electroconvulsive therapy in severe mood disorders: a naturalistic 3-year cohort study | Q37241733 |
| | SSRIs, bone mineral density, and risk of fractures--a review | Q37525579 |
| | Therapeutic options in treatment-resistant depression | Q37881968 |
| | Can effects of antidepressants in patients with mild depression be considered as clinically significant? | Q37884961 |
| | A practical guide to the use of repetitive transcranial magnetic stimulation in the treatment of depression | Q37950782 |
| | Diagnostic conversions from major depressive disorder into bipolar disorder in an outpatient setting: results of a retrospective chart review | Q38032659 |
| | Depressive disorders and suicide: Epidemiology, risk factors, and burden | Q38073521 |
| | Lifestyle management of unipolar depression | Q38099044 |
| | World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders | Q38123516 |
| | Role of lithium augmentation in the management of major depressive disorder | Q38192967 |
| | A systematic review of the clinical relevance of repetitive transcranial magnetic stimulation | Q38203934 |
| | Lithium in the treatment of major depressive disorder | Q38211605 |
| | Exploratory meta-analysis on deep brain stimulation in treatment-resistant depression | Q38250628 |
| | Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial | Q38379478 |
| | Risk factors for antidepressant-related switch to mania. | Q38474943 |
| | Increasing rates of depression | Q38610974 |
| | Lithium prophylaxis: myths and realities | Q38623725 |
| | Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? | Q40750612 |
| | Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis | Q40783243 |
| | Forty years of lithium treatment | Q40915654 |
| | Antidepressant-induced mania and cycle acceleration: a controversy revisited | Q40977115 |
| P433 | issue | 2 | |
| P921 | main subject | biological psychiatry | Q2706176 |
| P304 | page(s) | 76-95 | |
| P577 | publication date | 2015-02-01 | |
| P1433 | published in | World Journal of Biological Psychiatry | Q15759917 |
| P1476 | title | World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015. | |
| P478 | volume | 16 | |